Marnix Mylemans1, Louis Nevejan1, Stefanie Van Den Bremt1, Muriel Stubbe2, Bert Vander Cruyssen2, Christina Moulakakis3, Heike Berthold3, Christian Konrad3, Xavier Bossuyt4, Lieve Van Hoovels5. 1. Department of Laboratory Medicine, OLV Hospital, Aalst, Belgium. 2. Department of Rheumatology, OLV Hospital, Aalst, Belgium. 3. Thermo Fisher Scientific, Freiburg, Germany. 4. Department of Laboratory Medicine, University Hospital Leuven, Leuven, Belgium; Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium. 5. Department of Laboratory Medicine, OLV Hospital, Aalst, Belgium; Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium. Electronic address: lieve.van.hoovels@olvz-aalst.be.
Abstract
BACKGROUND: Calprotectin (CLP) is a promising biomarker for the evaluation of neutrophil-related inflammation. Our aim was to establish reference values for circulating CLP in different sample types and to study the effect of pre-analytical variables. METHODS: Reference values were determined in 100 healthy individuals. Pre-analytical variables were evaluated in 10 healthy controls and four rheumatoid arthritis patients with active disease and covered sample type (serum with/without gel separator, heparin, EDTA and citrate plasma), pre-centrifugation time (<2 h, 6 h, 24 h), storage condition (2-8 °C, 18-25 °C, 30 °C) and storage time (24 h, 72 h, 7 days). CLP measurements were performed with the EliA™Calprotectin 2 assay on Phadia™200 (Thermo Fisher Scientific). RESULTS: In healthy controls, baseline CLP concentrations in serum were more than double the concentration in EDTA and citrate plasma (0.909 µg/mL versus 0.259 µg/mL and 0.261 µg/mL respectively). Heparin, EDTA and citrate stabilized CLP concentrations for up to 6 h before centrifugation, whereas significant increases in CLP levels were observed when serum was left untreated during that time period. CONCLUSION: Clinical studies on circulating CLP need to apply sample type-specific reference values and decision limits. To obtain reproducible CLP results in serum, more stringent pre-analytical sample handling instructions are needed.
BACKGROUND: Calprotectin (CLP) is a promising biomarker for the evaluation of neutrophil-related inflammation. Our aim was to establish reference values for circulating CLP in different sample types and to study the effect of pre-analytical variables. METHODS: Reference values were determined in 100 healthy individuals. Pre-analytical variables were evaluated in 10 healthy controls and four rheumatoid arthritispatients with active disease and covered sample type (serum with/without gel separator, heparin, EDTA and citrate plasma), pre-centrifugation time (<2 h, 6 h, 24 h), storage condition (2-8 °C, 18-25 °C, 30 °C) and storage time (24 h, 72 h, 7 days). CLP measurements were performed with the EliA™Calprotectin 2 assay on Phadia™200 (Thermo Fisher Scientific). RESULTS: In healthy controls, baseline CLP concentrations in serum were more than double the concentration in EDTA and citrate plasma (0.909 µg/mL versus 0.259 µg/mL and 0.261 µg/mL respectively). Heparin, EDTA and citrate stabilized CLP concentrations for up to 6 h before centrifugation, whereas significant increases in CLP levels were observed when serum was left untreated during that time period. CONCLUSION: Clinical studies on circulating CLP need to apply sample type-specific reference values and decision limits. To obtain reproducible CLP results in serum, more stringent pre-analytical sample handling instructions are needed.
Authors: Gary L Norman; Sherwin A Navaz; Yogendra Kanthi; Roger Albesa; Michael Mahler; Jason S Knight; Yu Zuo Journal: Diagnostics (Basel) Date: 2022-05-27
Authors: Luis García de Guadiana-Romualdo; Carlos Rodríguez Rojas; Daniel Morell-García; David Andaluz-Ojeda; María Dolores Rodríguez Mulero; Enrique Rodríguez-Borja; Antonieta Ballesteros-Vizoso; María Dolores Calvo; Lourdes Albert-Botella; Adela Pozo Giráldez; Isabel Llompart-Alabern; Cristina Bolado Jiménez; Marta Hernández Olivo; Lucía Fernández Presa; Juan Ortega-Pérez; María José Fora Romero; Valerio Campos-Rodríguez; Andrea Ballester Férriz; Alexandra M Guiu-Martí; Leyre Pinilla Arribas; María Galindo Martínez; Edwin R Puerto-Lara; Ana Belen López Tarazaga; María Salomé Ros Braquehais; Leonor Nogales Martín; Celia Juez Santamaría; Wysalli Trapiello Fernández; Virginia Espinilla Fernández; Aleksandra Havelka; María Dolores Albaladejo-Otón Journal: Inflamm Res Date: 2021-10-30 Impact factor: 6.986
Authors: Michael Gernert; Marc Schmalzing; Hans-Peter Tony; Patrick-Pascal Strunz; Eva Christina Schwaneck; Matthias Fröhlich Journal: Arthritis Res Ther Date: 2022-08-19 Impact factor: 5.606